If you are comparing the daily tablet against the weekly injection, you have probably already decided what you want the answer to be. You want the tablet to work as well as the injection, because a pill is easier to live with than a needle. The two drugs are oral semaglutide, swallowed daily, and tirzepatide, injected once a week. Here is the honest answer, and it has two halves. On the clinical evidence, tirzepatide is the stronger agent for weight, and it is not close: 20.2 percent average weight reduction against 13.7 percent for the semaglutide molecule in the one trial that compared them. On what is actually licensed in Singapore, the gap is wider still, because only one of the two is registered here for weight management at all. Both halves are below, including the part where oral semaglutide is the better choice.
One thing to say plainly up front: Nexus does not prescribe the oral tablet. This is an explainer, not an offer, and there is nothing here we are trying to sell you.
Key takeaways
- The tablet and the weekly injection are not two versions of one drug. One is oral semaglutide, a single GLP-1 receptor agonist taken daily. The other is tirzepatide, a dual GIP and GLP-1 receptor agonist injected once a week.
- In Singapore, tirzepatide carries a registered weight management indication. Oral semaglutide does not. Its registration here covers type 2 diabetes only.
- No trial has ever compared the two head to head. Any single number offered for that comparison is describing a study that does not exist.
- Indirect evidence still points one way. Tirzepatide reduced weight 20.2 percent against 13.7 percent for injectable semaglutide over 72 weeks. Oral semaglutide at 14 mg moved weight 2.3 kg against placebo at 26 weeks.
- The tablet is not a weak drug. It is a real option for blood sugar control in type 2 diabetes, and the strongest medicine is worth nothing if a needle means you never start.
Tablet or weekly injection? The 30-second answer
If your goal is weight loss and you are in Singapore, the once-weekly injection is the one with a licence for that job. The oral tablet is registered here to improve blood sugar control in type 2 diabetes, and nothing else. That is not a comment on how well it works. It is a statement about what it is approved to treat, and it shapes what any doctor here can responsibly prescribe it for.
If your goal is better blood sugar control in type 2 diabetes and you genuinely cannot manage an injection, the tablet is a real and registered option. A daily tablet you actually take beats a weekly injection you keep postponing.
The difference that decides it in Singapore
This is the section the other comparison pages miss, because most of them are written for readers in the United States, where the regulator and the answers are different.
Singapore's National Drug Formulary records a registered indication for every product. The oral semaglutide tablets registered here, at 3 mg and 7 mg, are indicated “for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise”. Weight is not in that sentence.
The once-weekly tirzepatide pen carries two indications. Alongside type 2 diabetes, it is registered “as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of 30 kg/m2 and above (obesity) or 27 to under 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition”, per its Singapore registration record.
So when someone asks which is better for weight loss, the first answer is not about potency. One of them is licensed for the indication and the other is not. Using the tablet for weight alone is off-label prescribing, which is a decision a doctor has to make deliberately and explain to you, not a default.
What the trials show, and the study that does not exist
Start with the caveat, because it is the thing you will not read on most pages ranking for this question. No randomised trial has ever compared the daily tablet against the weekly injection. Every comparison between them, including this one, is indirect. It stitches together separate trials run in different populations against different comparators, and indirect comparison is weaker evidence than a head-to-head. Anyone quoting you one clean number for this matchup is quoting something that was never measured.
What we do have is this.
Read that table carefully, because the two weight figures are not like for like. The first is a placebo-adjusted difference in kilograms over 26 weeks in people with type 2 diabetes. The second is a percentage change from baseline over 72 weeks in people with obesity and without diabetes. Different populations, different durations, different units. They cannot be subtracted from one another. Use them for scale, never as a scoreline.
Why tirzepatide pulls ahead of oral semaglutide on weight
The cleanest evidence comes from the trial where tirzepatide was tested directly against semaglutide, though the semaglutide in it was the injection rather than the tablet.
In SURMOUNT-5, published in the New England Journal of Medicine in 2025, 751 adults with obesity and without type 2 diabetes were randomised to the maximum tolerated dose of either drug for 72 weeks. Mean weight change was 20.2 percent with tirzepatide against 13.7 percent with injectable semaglutide. Waist circumference fell 18.4 cm against 13.0 cm. In type 2 diabetes, SURPASS-2 randomised 1,879 patients over 40 weeks and found tirzepatide better on HbA1c at every dose, with weight differences of 1.9 kg, 3.6 kg and 5.5 kg favouring the 5 mg, 10 mg and 15 mg arms.
The mechanism explains the pattern. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and on GIP, a second incretin receptor, which appears to add to the effect on appetite and energy balance. Two levers rather than one.
If you are after the practical side instead, our guide to tirzepatide in Singapore covers what it costs and how it is accessed.
Now apply that to the tablet, which is the same semaglutide molecule taken by a harder route.
Why oral semaglutide is so hard for the body to absorb
This is worth understanding, because it explains most of the gap and almost nobody covers it.
Semaglutide is a peptide, a small chain of amino acids. Your stomach is built to break peptides down; that is what it does to the protein in your breakfast. Swallow a peptide on its own and very little of it survives to reach the bloodstream. That is the reason this entire drug class started as injections. We go through how semaglutide works on the GLP-1 receptor separately.
The tablet solves it with an absorption enhancer that raises the local pH in a small patch of the stomach lining and shields the molecule long enough to cross. It works, but it works narrowly, and it comes with conditions:
- It has to be taken on waking, on an empty stomach.
- With no more than about half a glass of plain water.
- With nothing else by mouth, food, drink or other tablets, for at least 30 minutes afterwards.
Follow that and absorption is still modest and variable between people. Miss the window regularly and it drops further. So the tablet is a less potent molecule delivered by a less efficient route, and the dose reaching your bloodstream is a fraction of what the same milligrams would deliver by injection. That is why the gap on weight is wide rather than marginal, and it is not a manufacturing flaw. It is chemistry.
Why that 16 percent figure is misleading
If you have seen a figure of around 16 percent attached to an oral GLP-1 tablet, it is worth knowing where it comes from before you carry it into a conversation with your doctor.
A 25 mg oral semaglutide tablet was tested for obesity in the OASIS 4 trial, published in 2025. It produced a 13.6 percent mean weight reduction at 64 weeks against 2.2 percent for placebo. The higher 16.6 percent figure that circulates is the full-adherence analysis, not the trial's primary result.
Either way, that is a different product from the oral doses registered in Singapore, which stop at 14 mg and are approved for diabetes. A strong result at 25 mg tells you very little about a 7 mg tablet prescribed here for a different condition. Check which dose any oral figure refers to before you rely on it.
Where oral semaglutide is the better choice
A comparison that only runs one way is a sales pitch, so here is the other side, and it matters more than it usually gets credit for.
Adherence beats potency when the potent option never gets taken. Some people will not inject. Not “would rather not”, but will not, and no amount of coaching changes it. For that person a registered daily tablet that controls blood sugar is real treatment, and the theoretically stronger weekly injection they never start is not.
There are practical advantages too. A tablet needs no sharps disposal and no refrigeration, which matters if you travel often or share a fridge you would rather not explain. Titration is finer at the low end, which can help someone who has had a rough time with gastrointestinal side effects before. And in type 2 diabetes, which is what it is licensed for here, it does the job it was approved to do: 77 percent of patients on the 14 mg dose reached an HbA1c below 7 percent in the PIONEER programme.
The trade is the ritual. The morning window is unforgiving, and a weekly injection asks for two minutes once a week. For plenty of people that is the easier discipline. Worth thinking about honestly before you assume the pill is the gentler option.
What a doctor checks before prescribing either
Before either medication becomes a plan, the consultation covers baseline blood work, your weight history and what you have already tried, current medications, and any personal or family history of medullary thyroid carcinoma or MEN 2, which rules out this drug class entirely. Pregnancy, planned pregnancy and breastfeeding rule it out as well. A history of pancreatitis, gallbladder disease or diabetic retinopathy each change the risk conversation without necessarily ending it.
Neither drug is a standalone answer. Both are prescribed alongside changes to diet and activity, and both are reviewed on a schedule rather than repeated indefinitely without reassessment.
What the side effects are, and what happens when you stop
Both share a side effect profile driven by the same receptor. Gastrointestinal effects are the common ones: nausea, diarrhoea, vomiting, constipation, mostly mild to moderate, mostly during dose escalation, mostly settling. In SURPASS-2, nausea was reported in 17 to 22 percent of the tirzepatide groups and 18 percent of the semaglutide group. In OASIS 4, gastrointestinal events occurred in 74.0 percent of the oral arm against 42.2 percent on placebo.
The serious risks are class-wide rather than specific to either: pancreatitis, gallbladder disease, and the thyroid C-cell contraindication above.
On stopping, appetite regulation returns to roughly where it was. Weight regain after discontinuation is consistently observed across this drug class. That does not mean you are on it for life, but it does mean stopping is a planned step with a maintenance strategy attached, not simply not renewing a prescription. That is a conversation to have at the start, not at month nine.
What to ask your doctor before you decide
- Which are we treating first, my blood sugar or my weight, and does that change which drug is appropriate?
- Is what you are proposing registered in Singapore for that indication, and if not, why is off-label use the right call for me?
- What is the plan if I cannot tolerate the dose escalation, and at what point do we stop?
- What happens to my weight when I come off it, and what does maintenance look like?
- What are we measuring, and how often, so we know whether this is working?
Frequently asked questions
Readers arrive at this question by brand name, so here is the mapping and what separates the two. This table reports what the trials measured and what each product is registered for in Singapore. It is not a recommendation, and which one suits you is a prescribing decision made after an assessment.
Common questions about the tablet and the weekly injection
Choosing between a daily tablet and a weekly injection is not really a choice between two strengths. It is a choice about what you are treating, what is licensed to treat it here, and what you will realistically keep doing. Nexus runs a doctor-supervised weight loss programme built on the once-weekly injection, and if you want that read against your own bloods and history rather than against a table, a consultation is where it starts.
